Order Article Reprints

Kobayashi M, Numakura K, Hatakeyama S, Muto Y, Sekine Y, Sasagawa H, Kashima S, Yamamoto R, Koizumi A, Nara T, et al. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. Genes. 2022; 13(7):1204. https://doi.org/10.3390/genes13071204

Kobayashi, Mizuki, Kazuyuki Numakura, Shingo Hatakeyama, Yumina Muto, Yuya Sekine, Hajime Sasagawa, Soki Kashima, Ryohei Yamamoto, Atsushi Koizumi, Taketoshi Nara, and et al. 2022. "Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism" Genes 13, no. 7: 1204. https://doi.org/10.3390/genes13071204

Kobayashi, M., Numakura, K., Hatakeyama, S., Muto, Y., Sekine, Y., Sasagawa, H., Kashima, S., Yamamoto, R., Koizumi, A., Nara, T., Saito, M., Narita, S., Ohyama, C., & Habuchi, T. (2022). Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. Genes, 13(7), 1204. https://doi.org/10.3390/genes13071204